Evidence map›Paper›PMID 24832084›Full record

SynthesisCarcinogenesis2014

Cross-cancer pleiotropic analysis of endometrial cancer: PAGE and E2C2 consortia.

Veronica Wendy Setiawan, Fredrick Schumacher, Jennifer Prescott, Jeffrey Haessler, Jennifer Malinowski, Nicolas Wentzensen, Hannah Yang, Stephen Chanock, Louise Brinton, Patricia Hartge and 24 more

Open access · bronzeAbstract readComparative StudyMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Carcinogenesis, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Identification of Pleiotropic Cancer Susceptibility Variants from Genome-Wide Association Studies Reveals Functional Characteristics.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2018
    Article
  5. Article
  6. Article
  7. Data analysis in the post-genome-wide association study era.Chronic diseases and translational medicine · 2016
    Review
  8. Review
  9. Pleiotropic analysis of cancer risk loci on esophageal adenocarcinoma risk.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2015
    Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors at 9 institutions in 1 country.

Veronica Wendy SetiawanDepartment of Preventive Medicine, Keck School of Medicine, and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90089, USA, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA, Center for Human Genetics Research, Vanderbilt University, Nashville, TN 37235, USA, National Cancer Institute, Bethesda, MD 20892, USA, M.Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, 02-781 Warsaw, Poland, Cancer Prevention Institute of California, Fremont, CA 94538, USA, Institute of Population Based Cancer Research, Cancer Registry of Norway, N-0304 Oslo, Norway, Division of Cancer Etiology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA, Department of Epidemiology, Yale School of Public Health, New Haven CT 06520, USA, Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI 96813, USA, Division of Research, Kaiser Permanente Northern California, Oakland, CA 94611, USA, Section of Biostatistics and Epidemiology, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Lebanon, NH 03756, USA, Division of Endocrinology, Diabetes and Metabolism, Ohio State University, Columbus, OH 43210, USA, Department of Obstetrics and Gynecology, University of California, Davis, CA 95616, USA, Department of Oncology, Wayne State University School of Medicine and Population Studies and Disparities Research, Karmanos Cancer Institute, Detroit, MI 48202, USA and Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA vsetiawa@usc.edu.
Fredrick SchumacherDepartment of Preventive Medicine, Keck School of Medicine, and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90089, USA, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA, Center for Human Genetics Research, Vanderbilt University, Nashville, TN 37235, USA, National Cancer Institute, Bethesda, MD 20892, USA, M.Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, 02-781 Warsaw, Poland, Cancer Prevention Institute of California, Fremont, CA 94538, USA, Institute of Population Based Cancer Research, Cancer Registry of Norway, N-0304 Oslo, Norway, Division of Cancer Etiology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA, Department of Epidemiology, Yale School of Public Health, New Haven CT 06520, USA, Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI 96813, USA, Division of Research, Kaiser Permanente Northern California, Oakland, CA 94611, USA, Section of Biostatistics and Epidemiology, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Lebanon, NH 03756, USA, Division of Endocrinology, Diabetes and Metabolism, Ohio State University, Columbus, OH 43210, USA, Department of Obstetrics and Gynecology, University of California, Davis, CA 95616, USA, Department of Oncology, Wayne State University School of Medicine and Population Studies and Disparities Research, Karmanos Cancer Institute, Detroit, MI 48202, USA and Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA.
Jennifer PrescottBrigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Jeffrey HaesslerDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Jennifer MalinowskiCenter for Human Genetics Research, Vanderbilt University, Nashville, TN 37235, USA.
Nicolas WentzensenNational Cancer Institute, Bethesda, MD 20892, USA.
Hannah YangNational Cancer Institute, Bethesda, MD 20892, USA.
Stephen ChanockNational Cancer Institute, Bethesda, MD 20892, USA.
Louise BrintonNational Cancer Institute, Bethesda, MD 20892, USA.
Patricia HartgeNational Cancer Institute, Bethesda, MD 20892, USA.
Jolanta LissowskaM.Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, 02-781 Warsaw, Poland.
S Lani ParkDepartment of Preventive Medicine, Keck School of Medicine, and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90089, USA, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA, Center for Human Genetics Research, Vanderbilt University, Nashville, TN 37235, USA, National Cancer Institute, Bethesda, MD 20892, USA, M.Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, 02-781 Warsaw, Poland, Cancer Prevention Institute of California, Fremont, CA 94538, USA, Institute of Population Based Cancer Research, Cancer Registry of Norway, N-0304 Oslo, Norway, Division of Cancer Etiology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA, Department of Epidemiology, Yale School of Public Health, New Haven CT 06520, USA, Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI 96813, USA, Division of Research, Kaiser Permanente Northern California, Oakland, CA 94611, USA, Section of Biostatistics and Epidemiology, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Lebanon, NH 03756, USA, Division of Endocrinology, Diabetes and Metabolism, Ohio State University, Columbus, OH 43210, USA, Department of Obstetrics and Gynecology, University of California, Davis, CA 95616, USA, Department of Oncology, Wayne State University School of Medicine and Population Studies and Disparities Research, Karmanos Cancer Institute, Detroit, MI 48202, USA and Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA.
Iona ChengCancer Prevention Institute of California, Fremont, CA 94538, USA.
William S BushCenter for Human Genetics Research, Vanderbilt University, Nashville, TN 37235, USA.
Dana C CrawfordCenter for Human Genetics Research, Vanderbilt University, Nashville, TN 37235, USA.
Giske UrsinInstitute of Population Based Cancer Research, Cancer Registry of Norway, N-0304 Oslo, Norway.
Pamela Horn-RossCancer Prevention Institute of California, Fremont, CA 94538, USA.
Leslie BernsteinDivision of Cancer Etiology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA.
Lingeng LuDepartment of Epidemiology, Yale School of Public Health, New Haven CT 06520, USA.
Harvey RischDepartment of Epidemiology, Yale School of Public Health, New Haven CT 06520, USA.
Herbert YuCancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI 96813, USA.
Lori C SakodaDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA, Division of Research, Kaiser Permanente Northern California, Oakland, CA 94611, USA.
Jennifer DohertyDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA, Section of Biostatistics and Epidemiology, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Lebanon, NH 03756, USA.
Chu ChenDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Rebecca JacksonDivision of Endocrinology, Diabetes and Metabolism, Ohio State University, Columbus, OH 43210, USA.
Shagufta YasmeenDepartment of Obstetrics and Gynecology, University of California, Davis, CA 95616, USA.
Michele CoteDepartment of Oncology, Wayne State University School of Medicine and Population Studies and Disparities Research, Karmanos Cancer Institute, Detroit, MI 48202, USA and.
Jonathan M KocarnikDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Ulrike PetersDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Peter KraftBrigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA, Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA.
Immaculata De VivoBrigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA, Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA.
Christopher A HaimanDepartment of Preventive Medicine, Keck School of Medicine, and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA 90089, USA, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA, Center for Human Genetics Research, Vanderbilt University, Nashville, TN 37235, USA, National Cancer Institute, Bethesda, MD 20892, USA, M.Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, 02-781 Warsaw, Poland, Cancer Prevention Institute of California, Fremont, CA 94538, USA, Institute of Population Based Cancer Research, Cancer Registry of Norway, N-0304 Oslo, Norway, Division of Cancer Etiology, Beckman Research Institute of City of Hope, Duarte, CA 91010, USA, Department of Epidemiology, Yale School of Public Health, New Haven CT 06520, USA, Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI 96813, USA, Division of Research, Kaiser Permanente Northern California, Oakland, CA 94611, USA, Section of Biostatistics and Epidemiology, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Lebanon, NH 03756, USA, Division of Endocrinology, Diabetes and Metabolism, Ohio State University, Columbus, OH 43210, USA, Department of Obstetrics and Gynecology, University of California, Davis, CA 95616, USA, Department of Oncology, Wayne State University School of Medicine and Population Studies and Disparities Research, Karmanos Cancer Institute, Detroit, MI 48202, USA and Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA.
Charles KooperbergDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Loic Le MarchandCancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI 96813, USA.
Fred Hutch Cancer Center · USNational Cancer Institute · USCancer Prevention Institute of California · USHarvard University · USThe Ohio State University · USUniversity of California, Davis · USUniversity of Hawaiʻi at Mānoa · USUniversity of Hawaii System · USWayne State University · US

Funding

Hormone-Related CancersZIACP010126 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GIERACH, GRETCHEN · 2009 to 2025
$103.5M
Yale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI MEGAN C KING · 1985 to 2026
$85.0M
Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ROSNER, BERNARD A · 2000 to 2019
$77.8M
University of Hawaii Cancer Center CCSGP30CA071789 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI GERTRAUD MASKARINEC · 1996 to 2026
$56.2M
The Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4M
CALIFORNIA TEACHERS STUDYR01CA077398 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BERNSTEIN, LESLIE · 1998 to 2014
$29.7M
Multiethnic Cohort Study of Diet and CancerR37CA054281 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI KOLONEL, LAURENCE N. · 2003 to 2012
$23.2M
Women's Health Initiative Clinical Coordinating CenterN01WH22110 · WH · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PRENTICE, ROSS L · 2007 to 2010
$22.5M
BIOCHEMICAL MARKERS IN THE NURSES'HEALTH STUDY COHORTR01CA049449 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI HANKINSON, SUSAN E · 1989 to 2008
$11.3M
Epidemiology of putative genuine genetic variant: The Women's Health IntiativeU01HG004790 · NHGRI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KOOPERBERG, CHARLES L · 2008 to 2012
$9.9M
Genetic Epidemiology of Causal Variants Across the Life CourseU01HG004803 · NHGRI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI NORTH, KARI E. · 2008 to 2012
$9.0M
Epidemiologic Architecture for Genes Linked to Environment (EAGLE)U01HG004798 · NHGRI · VANDERBILT UNIVERSITY · PI CRAWFORD, DANA C · 2008 to 2013
$8.8M
Intramural NIH HHSNCATS NIH HHS UL1 TR000445NCI NIH HHS K05 CA092002NCI NIH HHS K05 CA 92002NCI NIH HHS P01 CA087969NCI NIH HHS P01 CA87969NCI NIH HHS P30 CA071789NCI NIH HHS R01 CA049449NCI NIH HHS R01 CA077398NCI NIH HHS R01 CA082838NCI NIH HHS R01CA082838NCI NIH HHS R01 CA087538NCI NIH HHS R01 CA091019NCI NIH HHS R01 CA098346NCI NIH HHS R01 CA105212NCI NIH HHS R01 CA134958NCI NIH HHS R01 CA49449NCI NIH HHS R01 CA75977NCI NIH HHS R01 CA77398NCI NIH HHS R01 CA87538NCI NIH HHS R01 CA91019NCI NIH HHS R03 CA080636NCI NIH HHS R03 CA80636NCI NIH HHS R35 CA39779NCI NIH HHS R37 CA054281NCI NIH HHS R37CA54281NHGRI NIH HHS U01 HG004790NHGRI NIH HHS U01HG004790NHGRI NIH HHS U01 HG004798NHGRI NIH HHS U01HG004798NHGRI NIH HHS U01 HG004802NHGRI NIH HHS U01HG004802NHGRI NIH HHS U01 HG004803NHGRI NIH HHS U01HG004803NHGRI NIH HHS U01 HG007376NHGRI NIH HHS U01HG0S04801NICHD NIH HHS N01 HD023166NICHD NIH HHS N01 HD 2 3166NIGMS NIH HHS T32 GM080178WHI NIH HHS N01 WH022110WHI NIH HHS N01WH22110WHI NIH HHS N01WH24152WHI NIH HHS N01WH32100WHI NIH HHS N01WH32101WHI NIH HHS N01WH32102WHI NIH HHS N01WH32105WHI NIH HHS N01WH32106WHI NIH HHS N01WH32108WHI NIH HHS N01WH32109WHI NIH HHS N01WH32111WHI NIH HHS N01WH32112WHI NIH HHS N01WH32113WHI NIH HHS N01WH32115WHI NIH HHS N01WH32118WHI NIH HHS N01WH32119WHI NIH HHS N01WH32122WHI NIH HHS N01WH42107WHI NIH HHS N01WH42108WHI NIH HHS N01WH42109WHI NIH HHS N01WH42110WHI NIH HHS N01WH42111WHI NIH HHS N01WH42112WHI NIH HHS N01WH42113WHI NIH HHS N01WH42114WHI NIH HHS N01WH42115WHI NIH HHS N01WH42116WHI NIH HHS N01WH42117WHI NIH HHS N01WH42118WHI NIH HHS N01WH42119WHI NIH HHS N01WH42120WHI NIH HHS N01WH42121WHI NIH HHS N01WH42122WHI NIH HHS N01WH42123WHI NIH HHS N01WH42124WHI NIH HHS N01WH42125WHI NIH HHS N01WH42126WHI NIH HHS N01WH42129WHI NIH HHS N01WH42130WHI NIH HHS N01WH42131WHI NIH HHS N01WH42132WHI NIH HHS N01WH42221
6 · The paper itself

Abstract

Genome-wide association studies (GWAS) have identified a large number of cancer-associated single nucleotide polymorphisms (SNPs), several of which have been associated with multiple cancer sites suggesting pleiotropic effects and shared biological mechanisms across some cancers. We hypothesized that SNPs associated with other cancers may be additionally associated with endometrial cancer. We examined 213 SNPs previously associated with 14 other cancers for their associations with endometrial cancer in 3758 endometrial cancer cases and 5966 controls of European ancestry from two consortia: Population Architecture Using Genomics and Epidemiology and the Epidemiology of Endometrial Cancer Consortium. Study-specific logistic regression estimates adjusted for age, body mass index and the most significant principal components of genetic ancestry were combined using fixed-effect meta-analysis to evaluate the association between each SNP and endometrial cancer risk. A Bonferroni-corrected P value of 2.35×10(-4) was used to determine statistical significance of the associations. SNP rs7679673, ~6.3kb upstream of TET2 and previously reported to be associated with prostate cancer risk, was associated with endometrial cancer risk in the direction opposite to that for prostate cancer [meta-analysis odds ratio = 0.87 (per copy of the C allele), 95% confidence interval = 0.81, 0.93; P = 7.37×10(-5)] with no evidence of heterogeneity across studies (P heterogeneity = 0.66). This pleiotropic analysis is the first to suggest TET2 as a susceptibility locus for endometrial cancer.

Indexed as

Polymorphism, Single NucleotideCase-Control StudiesDioxygenasesDNA-Binding ProteinsEndometrial NeoplasmsFemaleGenetic PleiotropyGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansProto-Oncogene ProteinsRisk FactorsDioxygenasesDNA-Binding ProteinsProto-Oncogene ProteinsTET2 protein, human

Identifiers

PMID24832084
PMCPMC4146418
OpenAlexW2100630465

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.